US Stock MarketDetailed Quotes

ASND Ascendis Pharma A/S

Watchlist
  • 135.430
  • +0.220+0.16%
Trading Jul 22 10:56 ET
7.74BMarket Cap-14028P/E (TTM)

Ascendis Pharma A/S Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Ascendis Pharma A/S Earnings Date

Currency: EUR

Period

Q1 FY2024 Earnings

May 2, 2024

Revenue(YoY)

95.89M

+185.49%
EPS(YoY)

-2.30

-16.16%
Analyst Rating

Strong Buy

Jul 22, 2024

Ascendis Pharma A/S Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 10 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: EUR

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 106.423M--
--2024/Q2-- / 87.571M--
May 2, 20242024/Q195.894M / 79.867M--
Feb 7, 20242023/Q4137.703M / 85.606M--
Nov 7, 20232023/Q348.034M / 47.991M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 106.423M--
--2024/Q2-- / 87.571M--
May 2, 20242024/Q195.894M / 79.867M--
Feb 7, 20242023/Q4137.703M / 85.606M--
Nov 7, 20232023/Q348.034M / 47.991M--

Unlock Free Earnings Estimates

Ascendis Pharma A/S Earnings Reports

  • Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)

    May 2 16:36 ET

  • Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)

    May 2 16:29 ET

  • Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)

    May 2 16:05 ET

  • Ascendis Pharma A/S | 20-F: Registration statement / Annual report / Transition report

    Feb 7 16:24 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 22, 2024

    Strong Buy

    • Buy

      81.82%

    • Hold

      18.18%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg